International regulators make dementia plans
This article was originally published in Scrip
The conclusions of a workshop involving 10 medicines regulators held in Geneva in November 2014 have been published by the UK's MHRA, which noted that the meeting was the first time the regulators had met globally to discuss dementia. With the aim of providing a supportive environment for drug development in this area of high unmet need, six areas were identified in which regulators and other clinical and scientific experts and analysts will collaborate to find a solution to the problem. These included analysing the factors behind the termination of development programs over the past 10-15 years; considering how to make clinical trials more efficient; composite endpoints and benefit-risk balance including exploring expedited approval procedures. Participants in the initial workshop included the European Medicines Agency and regulators from several countries including the US, Japan, Germany, Italy, Denmark, the UK, the Netherlands, Canada and Switzerland. The meeting was convened by the UK government, which is also supporting the World Health Organization's first ministerial conference on global action against dementia in Geneva on 16-17 March.
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.